Functional dyspepsia: A new Rome III paradigm

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 259-272

  Halder, Smita L S ^b   Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; ANTIBIOTIC AGENT; ANXIOLYTIC AGENT; BISMUTH; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CIMETIDINE; CISAPRIDE; CLOMIPRAMINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; FAMOTIDINE; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MELATONIN; METOCLOPRAMIDE; MIANSERIN; NARCOTIC ANALGESIC AGENT; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SEROTONIN AGONIST; SPASMOLYTIC AGENT; SUCRALFATE;

BLOATING; CELL PROTECTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PATHWAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EPIGASTRIC PAIN; ERADICATION THERAPY; FATIGUE; FOLLOW UP; HEART DISEASE; HEARTBURN; HELICOBACTER INFECTION; HERBAL MEDICINE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; NAUSEA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH FUNCTION; STOMACH MOTILITY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

EID: 34547567894     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0069-0     Document Type: Review

References (87)

1. Talley NJ, Stanghellini V, Heading RC, et al.: Functional gastroduodenal disorders. Gut 1999, 45(Suppl 2):II37-II42.
2. Locke GR 3rd: The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996, 25:1-19.
3. Nyren O, Lindberg G, Lindstrom E, et al.: Economic costs of functional dyspepsia. Pharmacoeconomics 1992, 1:312-324.
4. Moayyedi P, Mason J: Clinical and economic consequences of dyspepsia in the community. Gut 2002, 50(Suppl 4): iv10-iv12.
5. Armstrong D, Kazim F, Gervais M, Pyzyk M: Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice. Can J Gastroenterol 2002, 16:439-450.
6. Heading RC: Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999, 231:3-8.
7. Karamanolis G, Caenepeel P, Arts J, Tack J: Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006, 130:296-303.
8. Tack J, Talley NJ, Camilleri M, et al.: Functional gastroduodenal disorders. Gastroenterology 2006, 130:1466-1479.
9. Camilleri M, Dubois D, Coulie B, et al.: Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005, 3:543-552.
10. Stanghellini V, Tosetti C, Paternic A, et al.: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110:1036-1042.
11. Lee KJ, Kindt S, Tack J: Pathophysiology of functional dyspepsia. Best Pract Res Clin Gastroenterol 2004, 18:707-716.
12. Tack J, Caenepeel P, Fischler B, et al.: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121:526-535.
13. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999, 116:515-520.
14. Tack J, Demedts I, Dehondt G, et al.: Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002, 122:1738-1747.
15. Mearin F, Perez-Oliveras M, Perello A, et al.: Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005, 129:98-104.
16. Holtmann G, Siffert W, Haag S, et al.: G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004, 126:971-979.
17. Halder SL, Talley NJ: Treatment of functional dyspepsia. Curr Treat Options Gastroenterol 2005, 8:325-336.
18. Talley NJ, Quan C: Review article: Helicobacter pylori and nonulcer dyspepsia. Aliment Pharmacol Ther 2002, 16(Suppl 1):58-65.
19. Wolle K, Malfertheiner P: Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007, 21:315-324.
20. Moayyedi P, Soo S, Deeks J, et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, 2:CD002096.
21. Ford AC, Qume M, Moayyedi P, et al.: Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005, 128:1838-1844.
22. Moayyedi P, Delaney BC, Vakil N, et al.: The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004, 127:1329-1337.
23. Wang WH, Huang JQ, Zheng GF, et al.: Effects of protonpump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007, 5:178-185.
24. Moayyedi P, Soo S, Deeks J, et al.: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, 4:CDO01960.
25. Gotthard R, Bodemar G, Brodin U, et al.: Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988, 23:7-18.
26. Nyren O, Adami HO, Bates S, et al.: Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986, 314:339-343.
27. Tatsuta M, Iishi H, Nakaizumi A, et al.: Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pbarmacol Ther 1992, 6:221-228.
28. Corinaldesi R, Stanghellini V, Raid C, et al.: Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987, 28:300-305.
29. Kellow JE, Cowan H, Shuter B, et al.: Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995, 9:153-160.
30. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al.: A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in heticobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005, 100:1477-1488.
31. Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004, 127:1239-1255.
32. Jackson JL, O'Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
33. Tack J, Broekaert D, Coulie B, et al.: Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003, 17:603-608.
34. Loldrup D, Langemark M, Hansen HJ, et al.: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology (Berl) 1989, 99:1-7.
35. Mertz H, Fass R, Kodner A, et al.: Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998, 93:160-165.
36. Hojo M, Miwa H, Yokoyama T, et al.: Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005, 40:1036-1042.
37. Tindle HA, Davis RB, Phillips RS, et al.: Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005, 11:42-49.
38. Thompson Coon J, Ernst E: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002, 16:1689-1699.
39. Melzer J, Rosch W, Reichling J, et al.: Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004, 20:1279-1287.
40. Pilichiewicz AN, Horowitz M, Russo A, et al.: Effects of Iberogast((R)) on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007, 102:1-8.
41. Holtmann G, Adam B, Haag S, et al.: Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003, 18:1099-1105.
42. Song GH, Leng PH, Gwee KA, et al.: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005, 54:1402-1407.
43. Klupinska G, Poplawski T, Drzewoski J, et al.: Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol 2007, 41:270-274.
44. Haug TT, Svebak S, Wilhelmsen I, et al.: Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res 1994, 38:281-291.
45. Talley NJ, Fung LH, Gilligan IJ, et al.: Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Gastroenterology 1986, 90:886-892.
46. Haug TT, Svebak S, Hausken T, et al.: Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia. Psychosom Med 1994, 56:181-186.
47. Lorena SL, Tinois E, Brunerto SQ, et al.: Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: influence of gender and anxiety. J Clin Gastroenterol 2004, 38:230-236.
48. Camilleri M, Malagelada JR, Kao PC, et al.: Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986, 31:1169-1177.
49. Soo S, Moayyedi P, Deeks J, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005, 2:CD002301.
50. Haug TT, Wilhelmsen I, Svebak S, et al.: Psychotherapy in functional dyspepsia. J Psychosom Res 1994, 38:735-744.
51. Hamilton J, Guthrie E, Creed F, et al.: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119:661-669.
52. Calvert EL, Houghton LA, Cooper P, et al.: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123:1778-1785.
53. Bates S, Sjoden PO, Nyren O: Behavioral treatment of non-ulcer dyspepsia. Scand J Behav Ther 1988, 17:155-165.
54. Prior A, Colgan SM, Whorwell PJ: Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut 1990, 31:896-898.
55. Haag S, Senf W, Tagay S, et al.: Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther 2007, 25:973-986.
56. Gershon MD, Tack J: The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007, 132:397-414.
57. Tonini M, Pace F: Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006, 24:59-69.
58. Tack J, Piessevaux H, Coulie B, et al.: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998, 115:1346-1352.
59. Mertz H, Fullerton S, Naliboff B, et al.: Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998, 42:814-822.
60. Tack J, Coulie B, Wilmer A, et al.: Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000, 46:468-473.
61. Tack J, Caenepeel P, Corsetti M, et al.: Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004, 127:1058-1066.
62. Karamanolis G, Kindt S, Vos R, et al.: Effect of tegaserod on meal-related symptoms induced by the nutrient drink test in man [abstract]. Gastroenterology 2006, 130:T2032.
63. Camilleri M, Mayer EA, Drossman DA, et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1159.
64. Talley NJ, Van Zanten SV, Saez LR, et al.: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001, 15:525-537.
65. Mansi C, Borro P, Giacomini M, et al.: Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000, 14:561-569.
66. Distrutti E, Fiorucci S, Hauer SK, et al.: Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002, 16:613-622.
67. Mearin F, Rodrigo L, Perez-Mota A, et al.: Levosulpiride and cisapride in the treatment of dysmotitity-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004, 2:301-308.
68. Tsubouchi T, Saito T, Mizutani F, et al.: Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003, 306:787-793.
69. Holtmann G, Talley NJ, Liebregts T, et al.: A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006, 354:832-840.
70. Talley NJ, Tack JF, Ptak T, et al.: Efficacy and safety of itopride in functional dyspepsia: results of two phase III multicentre, randomized, double-blind, placebo-controlled trials [abstract]. Gastroenterology 2007, 132:641.
71. Choung RS, Talley NJ, Peterson J, et al.: A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007, 19:180-187.
72. Di Stefano M, Vos R, Klersy C, et al.: Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Am J Gastroenterol 2006, 101:2797-2804.
73. Sarnelli G, Sifrim D, Janssens J, Tack J: Influence of sildenafil on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol 2004, 287:G988-G992.
74. Tack J, Caenepeel P, Corserti M, Janssens J: Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004, 127:1058-1066.
75. Feinle C, Grundy D, Otto B, et al.: Relationship between increasing duodenal lipid doses, gastric perception, and plasma hormone levels in humans. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1217-R1223.
76. Moran TH, Kinzig KP: Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 2004, 286:G183-G188.
77. Feinle C, Meier O, Otto B, et al.: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001, 48:347-355.
78. Delvaux M, Louvel D, Lagier E, et al.: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116:38-45.
79. Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664-668.
80. Fraitag B, Homerin M, Hecketsweiler P: Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994, 39:1072-1077.
81. Delgado-Aros S, Chial HJ, Cremonini F, et al.: Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18:507-514.
82. Choung RS, Talley NJ, Chitkara DK, et al.: A randomized, double-blind, placebo-controlled trial to evaluate the effects of the kappa opioid agonist asimadoline versus placebo on global gastric function and dyspepsia score in patients with functional dyspepsia [abstract]. Gastroenterology 2007, 132:M1154.
83. Fioramonti J, Gaultier E, Toulouse M, et al.: Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003, 15:363-369.
84. Mayer EA, Tillisch K, Bradesi S: Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006, 24:919-933.
85. Duncan M, Davison JS, Sharkey KA: Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005, 22:667-683.
86. Bortolotti M, Coccia G, Grossi G, Miglioli M: The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002, 16:1075-1082.
87. Hammer J: Effect of repeated capsaicin ingestion on intestinal chemosensation and mechanosensation. Aliment Pharmacol Ther 2006, 24:679-686.